Biotec Pharmacon completes enrollment in diabetic ulcer trial

By Elaine Rigoli

Tampa, Fla., May 15 - Biotec Pharmacon has completed patient enrollment in a double-blinded, therapeutic exploratory clinical phase 2 trial to evaluate the efficacy of its soluble beta-1,3/1,6-glucan (SBG) on chronic foot ulcers in diabetic patients.

The trial, which is performed at hospitals in Archangelsk and St. Petersburg, Russia, involves 60 patients. Patient treatment and follow-up is expected to continue for about 16 weeks, and the data from the study will be reported in the fourth quarter of this year, according to a news release.

Diabetic patients often suffer from complicated ulcers due to dysfunctional immune cells. Biotec Pharmacon's concept for treatment of ulcers is based on the company's pharmaceutical compound SBG, which acts on immune cells to advance healing of the ulcers, the release said.

Biotec Pharmacon, with U.S. headquarters in Irvine, Calif., develops pharmaceutical products to treat immune-related diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.